Patents by Inventor Sanjia XU

Sanjia XU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF
    Publication number: 20230373963
    Abstract: Disclosed herein is 3-[(1H-pyrazol-4-yl) oxy] pyrazin-2-amine compounds of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of modulating, e.g.
    Type: Application
    Filed: September 29, 2021
    Publication date: November 23, 2023
    Inventors: Sanjia XU, Jing LI, Zhiwei WANG
  • HETEROCYCLIC COMPOUNDS AS STING MODULATORS
    Publication number: 20230212192
    Abstract: Disclosed herein are heterocyclic compounds that may be used as STING modulators, the process for synthesis and to the use of such compounds in treatment of various diseases including cancers.
    Type: Application
    Filed: May 27, 2021
    Publication date: July 6, 2023
    Inventors: Jing LI, Sanjia XU, Zhiwei WANG, Guoliang ZHANG, Ce WANG, Jianzhuang MIAO, Lina GU, Gang CHEN, Xiaosong YU
  • Modular synthesis of aminoglycosides
    Patent number: 11673907
    Abstract: The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 13, 2023
    Assignee: Revagenix, Inc.
    Inventors: Andrew Calabrese, Timothy Robert Kane, Darin Hildebrandt, Michael Lopez, Nikolai Evdokimov, Frederick Cohen, Malken Bayrakdarian, Sanjia Xu, Samuel Desjardins, Olivier Soueidan
  • AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF
    Publication number: 20220289712
    Abstract: Disclosed herein is an aminopyrazine compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.
    Type: Application
    Filed: August 20, 2020
    Publication date: September 15, 2022
    Inventors: Jing LI, Zhiwei WANG, Sanjia XU, Hanzi SUN, Ye LIU
  • HETEROCYCLIC COMPOUNDS AS STING MODULATORS
    Publication number: 20220289768
    Abstract: Disclosed herein are heterocyclic compounds that may be used as STING modulators, process for synthesis and to uses of such compounds in treatment of various diseases including cancers.
    Type: Application
    Filed: October 8, 2020
    Publication date: September 15, 2022
    Inventors: Jing LI, Zhiwei WANG, Lina GU, Sanjia XU
  • TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF
    Publication number: 20220267354
    Abstract: Disclosed herein is a tricyclic compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.
    Type: Application
    Filed: July 17, 2020
    Publication date: August 25, 2022
    Inventors: Jing LI, Zhiwei WANG, Sanjia XU
  • PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF
    Publication number: 20220267333
    Abstract: Disclosed herein is a compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.
    Type: Application
    Filed: July 3, 2020
    Publication date: August 25, 2022
    Inventors: Jing LI, Zhiwei WANG, Sanjia XU
  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20220251135
    Abstract: Disclosed herein are cyclic di-nucleotide compounds and derivatives thereof that may be useful as STING agonists, and a pharmaceutical composition comprising the same. Also disclosed herein is the process for synthesis and to uses of such cyclic di-nucleotide compounds in various diseases including cancer, HIV infection and HBV infection.
    Type: Application
    Filed: July 24, 2020
    Publication date: August 11, 2022
    Inventors: Jing LI, Zhiwei WANG, Lina GU, Sanjia XU